Modern Management of Advanced Pancreatic Cancer: Expert Answers to Frequently Asked Questions, Edition 2
Source: Modern Management of Advanced Pancreatic Cancer: Expert Guidance on Clinical Challenges

Module

Expert answers to frequently asked questions about modern clinical management of pancreatic cancer, including diagnosis and screening, neoadjuvant treatment, first-line and second-line therapy, and novel approaches such as combining immunotherapy with chemotherapy or radiation.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guidelines and clinical findings to select individualized therapies for patients with newly diagnosed advanced pancreatic cancer
  • Plan treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer

Topics covered include:

  • Chemotherapy
  • Radiation Therapy
  • Diagnosing and Screening
  • Immunotherapy
 

Program Directors

  • Tanios Bekaii-Saab
    MD, FACP
    Andrew H. Ko
    MD

Faculty

  • Milind Javle
    MD
    Dan Laheru
    MD
    Kenneth Yu
    MD, MSc
  • Release Date:
    January 02, 2018

Information on this Educational Activity

Program Directors

Tanios Bekaii-Saab, MD, FACP

Professor
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Celgene, Genentech, and Merrimack.

 

Andrew H. Ko, MD

Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Andrew H. Ko, MD, has disclosed that he has received consulting fees from New β Innovations and Seattle Genetics and funds for research support from Aduro Biotech, Celgene, Merrimack, and Prism Bio.

 

Faculty

Milind Javle, MD


Professor, Tenure Track
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Milind Javle, MD, has no real or apparent conflicts of interest to report.

 

Dan Laheru, MD


Professor of Oncology
Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Co-Director, Gastrointestinal Cancer Program
Co-Director, Skip Viragh Center for Pancreatic Cancer Research and Clinical Care
Member, Miller-Coulson Academy of Clinical Excellence
The Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Dan Laheru, MD, has no real or apparent conflicts of interest to report.

 

Kenneth Yu, MD, MSc


Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Weill Cornell Medical College
New York, New York
Adjunct Assistant Professor
Department of Pharmacology
University of Pennsylvania
Philadelphia, Pennsylvania
Clinical Fellow
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Kenneth Yu, MD, MSc, has disclosed that he has received consulting fees from Halozyme, Ipsen, and Merrimark and funds for research support from Halozyme.

 

Staff

Terrence Fagan, 


Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.

 

Krista Marcello, 


Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.